Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco ‎May 20

For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20 HASBROUCK HEIGHTS, NJ (May 2, 2018) Nymox Pharmaceutic al Corporation (NASDA Q:NYMX) is pleased to announce that there will be a Symposium on the Company's lead drug Fexapotide held at the Annual Meeting of the American Urological Association on May 20 in San Francisco. The Symposium is entitled: “Phase 3 Clinical Studies and Biology of Fexapotide Triflutate Office Injectable for BPH” and will feature a presentation reviewing therapeutic high lights from the Company’s extensive Phase III trials involving more than 970 patients in the United States. The presentation is chaired by Dr. Ronald Tutrone of Chesapeake Urology Research Associat es, Baltimore MD and a panel discussion with panel members including Dr. Mohamed Bidair, San Diego CA; Dr. Ivan Grunberger, New York NY; Dr. Alan Hay, Salem OR; Dr. Susan Kalota, Tucson AZ and Dr. Jeffrey Snyder, Denver CO. The Annual Meeting of the AUA is the largest urology meeting held annually in the US and brings together over a 4 day period urologists and health care providers, industry and interested parties from across the world with an expected attendance of over 16,000 visitors. Nymox's fexapotide has been shown to produce long-term improvements in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), a problem that afflicts an estimated 100 million or more men in the world. Fexapotide does not cause the annoying side e ffects and risks found with available treatments for BPH and has also been shown to lower the occurrence of surgery for BPH. Fexapotide is also in development for low grade prostate cancer. For more information please contact [email protected] or 800-936-9669. Forward Looking Statements To the extent that statem ents contained in this press release are not descripti ons of historical facts regarding Nymox, they ar e forward-looking statements reflecting t he current beliefs and expectations of mana gement made pursuant to the safe harbor provisions of the Private Secu rities Litigation Reform Act of 1995, including st atements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to tr eat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements invo lve substantial risks and uncert ainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinic al drug development process, including the regulatory approval proc ess, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapot ide, Nymox's commercialization plans and effo rts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause ac tual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Co mmission, including its Annual Report on Form 20-F for the year ended December 31, 2017, and its Quarterly Reports. NEWS RELEASE

The release as fetched from its publisher. nymox.com ↗